Review of the ATHOS 3 trial
Northwestern EM Blog
FEBRUARY 14, 2022
Mortality benefit is an extremely elusive goal in critical care research 1 but that doesn’t discount the fact that ATHOS 3 wasn’t designed to demonstrate an improvement in any patient-oriented outcome. In my personal practice, I make sure to optimize these and start vasopressin shortly after the initiation of norepinephrine.
Let's personalize your content